Novartis Cholesterol Drug Failure Triggers Sector-Wide Biopharma Selloff
A failed trial targeting Lp(a), a blood fat linked to heart attacks, dragged down rival drugmakers betting on the same approach.
Novartis's failed trial for a cholesterol-lowering drug that targets Lp(a) sparked a broad selloff across biopharma stocks betting on the same cardiovascular strategy.
BREAKING STORYBEARISH